Balversa 3 mg

BALVERSA 3 MG tablets contain erdafitinib, a targeted therapy used to treat specific types of cancer. This medication is designed to inhibit fibroblast growth factor receptors (FGFR), offering a precision approach to cancer treatment.

BALVERSA 3 MG tablets are primarily used in the treatment of certain cancers that are driven by fibroblast growth factor receptor (FGFR) mutations. This medication is intended for patients who have specific genetic markers that make them suitable candidates for this targeted therapy. Erdafitinib works by blocking the FGFR proteins, which can help slow down the growth and spread of cancer cells.

Common effects of BALVERSA 3 MG tablets may include fatigue, nausea, and changes in appetite. Some patients may also experience dry skin or hair loss. These effects can vary from person to person, and not everyone will experience them. It's important to monitor any changes and consult a healthcare provider if concerns arise.

BALVERSA 3 MG tablets should be handled with care and stored as directed. It's important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should be aware of potential side effects and report any severe or persistent symptoms to their healthcare provider immediately.

BALVERSA 3 MG tablets may interact with certain medications, including those that affect liver enzymes. It's important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, alcohol and other substances may affect the efficacy or safety of this medication.